Dialysis Equipment Market

On 31 January 2025, Baxter completed the sale of its kidney care business to private equity firm Carlyle for USD 3.80 billion, creating Vantive, a standalone company focused on dialysis with the world’s largest peritoneal dialysis franchise. The deal left the dialysis equipment market with two dedicated leaders, Fresenius Medical Care and Vantive, and a clear bet on the home: Vantive’s strategy rests on moving more of the world’s 4 million-plus dialysis patients out of clinics and into their own homes. Douglas Insights values the dialysis equipment market at USD 19.2 billion in 2025 and forecasts USD 32.7 billion by 2035, a compound growth rate of 5.45%. The receipt is about 624 million dialysis treatments in 2025 at an average of USD 30.83 of equipment and consumables per treatment. Treatments grow 4.2% a year as kidney failure rises with diabetes, hypertension and ageing, and as access expands in Asia, Latin America and Africa; revenue per treatment grows 1.2% a year as home therapies, high-flux dialyzers and connected machines replace basic equipment. The report sits within Douglas Insights coverage of medical devices and follows the published Douglas Insights research methodology.

What does the dialysis equipment market include?

The dialysis equipment market covers the machines and consumables used to clean the blood of people whose kidneys have failed, about 624 million treatments worth USD 19.2 billion in 2025. Dialyzers and bloodlines are the filters and tubing used and thrown away at each haemodialysis session. Haemodialysis (HD) machines and water systems include the dialysis machines in clinics and the reverse-osmosis systems that make ultra-pure water. Peritoneal dialysis (PD) solutions and sets include the bags of fluid and tubing patients use at home, by hand or with a cycler overnight. Home and portable platforms include PD cyclers, home HD systems and newer compact machines designed for patients to use themselves. The market spans in-centre haemodialysis, peritoneal dialysis and home haemodialysis, delivered in dialysis centres and hospitals and in home care. Dialysis services, clinic staff, drugs such as anaemia treatments (intravenous iron is sized in the Iron Supplements Market report), and transplants sit outside the boundary.

How did the Vantive spin-off change the dialysis equipment market?

The Vantive spin-off created a second dedicated dialysis company with a home-first strategy, and Douglas Insights estimates Vantive held about 20% of dialysis equipment value in 2025, most of it in peritoneal dialysis. Baxter’s filing on the completed sale confirms the USD 3.80 billion price and the transition agreements that keep supply running while Vantive builds its own functions. As an independent company, Vantive can invest in home platforms and digital patient management without competing for capital inside a diversified hospital supplier. Douglas Insights threads the spin-off through this report: it sharpens competition in home dialysis, it pushes Fresenius Medical Care and others to respond with their own home products, and Vantive’s success in winning home patients is one of the swings in the scenarios.

Why does home dialysis keep being promised?

Home dialysis keeps being promised because it can cost health systems less and give patients more freedom, yet Douglas Insights estimates only about 13% of dialysis patients worldwide were treated at home in 2025. In the United States, the Advancing American Kidney Health initiative set a goal in 2019 for 80% of new kidney failure patients to receive home dialysis or a transplant by 2025, but home dialysis rose only to about 15% of patients. Home treatment needs patient training, space for supplies, regular deliveries of bulky fluid and support from nurses, and many patients start dialysis in an emergency with no time to prepare. Countries such as Hong Kong, where a PD-first policy has put most patients on home PD, show what policy can achieve; most others have moved slowly.

What drives dialysis equipment demand to 2035?

Four drivers carry dialysis treatment growth of 4.2% a year, and rising kidney failure is the largest. Diabetes and high blood pressure cause most kidney failure, and more people live long enough to need dialysis. Douglas Insights estimates the number of people on dialysis worldwide grows about 4% a year, from about 4 million in 2025, and values dialyzers and bloodlines, used at every haemodialysis session, at USD 8.47 billion in 2025, 44% of the market, growing 4.9% a year. The International Diabetes Federation counted about 537 million adults with diabetes in 2021, and diabetes alone causes close to half of new kidney failure in many countries.

Emerging-market access is the second driver. In China, India, Southeast Asia and Africa, many people with kidney failure still cannot get dialysis, and governments are expanding insurance and building centres. India’s Pradhan Mantri National Dialysis Programme, launched in 2016, now offers free dialysis at district hospitals. Douglas Insights values Asia Pacific dialysis equipment at USD 5.77 billion in 2025, growing 6.8% a year, the fastest of any region. China’s national health insurance now covers most dialysis costs for urban patients, and hundreds of new centres open there each year.

The home shift is the third driver. Payment policies in the United States, the United Kingdom and parts of Asia reward home starts, and new platforms make home haemodialysis simpler. Douglas Insights values home and portable platforms at USD 1.54 billion in 2025 and models them growing 9.8% a year, the fastest of any product, and PD solutions and sets at USD 4.23 billion, growing 5.9% a year. In the United States, the ESRD Treatment Choices model, launched in January 2021, tied Medicare payments for dialysis facilities in about 30% of US regions to their home dialysis and transplant rates.

Fleet replacement is the fourth driver. Haemodialysis machines last about 7 to 10 years, and clinics replace them with connected machines that record every session and support high-volume haemodiafiltration. Douglas Insights values HD machines and water systems at USD 5.00 billion in 2025, growing 4.4% a year, and estimates about 12% of the installed base is replaced each year.

What could restrain dialysis equipment sales?

Three restraints remove about 0.9 points a year from dialysis equipment growth. Kidney-protecting drugs are the first. SGLT2 inhibitors and other new medicines slow kidney disease in people with diabetes and chronic kidney disease, and Douglas Insights estimates they could cut new dialysis starts in wealthy countries by 5% to 15% by 2035 against the trend. The curve-bend scenario assumes the stronger effect.

Payment pressure is the second restraint. Dialysis is paid through fixed bundles in the United States and tenders in Europe and Asia, so providers push hard on the price of every consumable. Douglas Insights holds like-for-like prices flat, with revenue per treatment rising only through mix, at 1.2% a year. Large dialysis chains, which treat a majority of US patients, negotiate multi-year supply contracts that lock in consumable prices, and Chinese volume-based procurement has cut dialyzer prices sharply in some provinces.

Transplants are the third restraint. Every successful kidney transplant ends a patient’s need for dialysis, and efforts to raise organ donation, including US rules to improve organ procurement performance, could modestly lower dialysis volumes. Douglas Insights estimates transplants remove about 2% of the dialysis population each year in wealthy countries.

Which dialysis equipment segments carry the value?

Dialyzers and bloodlines lead the dialysis equipment market with 44% of 2025 value, while home and portable platforms are the fastest-growing segment at 9.8% a year. Every product holds its share for a different reason.

Dialyzers and bloodlines are worth USD 8.47 billion in 2025. They lead because every haemodialysis session uses a new dialyzer and set of bloodlines, about 150 per patient a year.

HD machines and water systems are worth USD 5.00 billion in 2025. They are capital purchases replaced every 7 to 10 years, so growth follows clinic openings and replacement cycles at 4.4% a year.

PD solutions and sets are worth USD 4.23 billion in 2025, growing 5.9% a year as more patients start on home PD, each using four or five bags of fluid a day.

Home and portable platforms are worth USD 1.54 billion in 2025 and form the fastest-growing segment at 9.8% a year, as PD cyclers, home HD systems and compact machines spread.

How do modality and setting split dialysis equipment?

By modality, in-centre haemodialysis accounts for USD 15.0 billion (78%) of 2025 value, peritoneal dialysis for USD 3.27 billion (17%) and home haemodialysis for USD 962 million (5%). By setting, dialysis centres and hospitals account for USD 15.2 billion (79%), and home care for USD 4.04 billion (21%). Dialysis centres run most sessions in North America and Europe; hospitals carry a larger share in India, Africa and parts of Latin America, where standalone centres are fewer; and home care grows fastest everywhere policy supports it.

Why is peritoneal dialysis central to the home shift?

Peritoneal dialysis is central to the home shift because it needs no machine in its simplest form and no needles, and Douglas Insights estimates PD accounts for about 70% of home dialysis patients worldwide. Patients fill and drain their abdomen with sterile fluid four or five times a day, or overnight with a cycler, after one to two weeks of training. For health systems, PD usually costs less per patient-year than in-centre haemodialysis because it avoids clinic staff and buildings. For suppliers, each PD patient buys fluid and sets every day for years, a steady revenue stream that explains why Vantive was valued at nearly USD 4 billion. The main limits are the weight of fluid deliveries, infection risk and the need for patients to manage their own care, which is why most PD growth comes from countries that make it the default first option.

Which regions buy the most dialysis equipment?

North America buys 34% of dialysis equipment by value, USD 6.54 billion in 2025, while Asia Pacific grows fastest at 6.8% a year. The United States has more than 550,000 dialysis patients and high equipment spend per treatment. The region grows 4.6% a year.

Asia Pacific buys USD 5.77 billion and grows 6.8% a year, the fastest rate. China, Japan and Taiwan have large dialysis populations, and access is expanding quickly in China, India and Southeast Asia.

Europe buys USD 4.43 billion and grows 4.4% a year, with mature, tender-based markets and growing use of haemodiafiltration. Latin America buys USD 1.35 billion and grows 6.0%, led by Brazil and Mexico. The Middle East is the wildcard at USD 770 million and 6.6% a year, where diabetes rates are among the world’s highest. Africa buys USD 385 million and grows 6.4%, with most patients still unable to get regular dialysis.

Who are the leading dialysis equipment companies?

Douglas Insights estimates that the three largest dialysis equipment companies hold about 52% of 2025 value, led by Fresenius Medical Care at about 24%.

Advantage in dialysis equipment rests on installed base and consumable pull-through. Fresenius Medical Care sells machines and dialyzers into its own clinics and others; Vantive dominates PD, where each patient buys fluid every day; Nipro, Asahi Kasei and Nikkiso lead dialyzer manufacturing in Asia; B. Braun competes on engineering in Europe. Outset Medical leads simplified home and hospital HD systems, while Chinese makers such as Weigao and SWS win domestic tenders on price.

How is a dialysis treatment priced?

Dialysis equipment and consumables cost an average of USD 30.83 per treatment in 2025, and Douglas Insights expects about USD 34.70 by 2035. A haemodialysis session in a wealthy country uses USD 20 to USD 45 of dialyzer, bloodlines, needles and concentrate, plus a share of machine and water system costs; in India or China the same session may use USD 8 to USD 15. A day of home PD uses USD 30 to USD 60 of solutions and sets. A haemodialysis machine costs USD 12,000 to USD 30,000, a clinic water system USD 50,000 to USD 250,000, and a home HD system USD 20,000 to USD 40,000 plus supplies.

Which rules apply to dialysis equipment?

Dialysis equipment is regulated as medical devices: machines, dialyzers and PD systems need FDA clearance in the United States and CE marking under the EU Medical Device Regulation, and water quality must meet ISO 23500 standards. Payment rules shape the market as much as device rules: the US Medicare end-stage renal disease bundle pays a fixed amount per treatment, with adjustments for home dialysis training and new technology, and many countries buy consumables through national tenders.

How are connected machines changing dialysis equipment?

Connected machines are changing dialysis equipment by turning each session into data, and Douglas Insights estimates about 45% of haemodialysis machines installed in wealthy countries in 2025 could send treatment data automatically to clinic records. Connected PD cyclers let nurses check home patients’ treatments every day and spot problems before a hospital visit. Clinics use session data to adjust treatments, manage staff and prove quality to payers. Connectivity raises the price of machines modestly and brings new cybersecurity duties, but it is becoming a requirement in tenders, and it makes home dialysis safer, which supports the home shift.

How far could dialysis equipment reach under each scenario?

The base scenario takes the dialysis equipment market to USD 32.7 billion by 2035, with a range of USD 27.5 billion to USD 37.5 billion. The base case combines 4.2% treatment growth with 1.2% revenue-per-treatment growth for 5.45% a year. The curve-bend scenario assumes kidney-protecting drugs cut new patients faster and payment pressure deepens, setting the legs at 3.0% and 0.6% for USD 27.5 billion. The access-and-home scenario assumes faster access in emerging markets and a stronger home shift, setting the legs at 5.0% and 1.8% for USD 37.5 billion. Each 1-point change in treatment growth moves the 2035 figure by about USD 3.28 billion.

Douglas Exclusive: the home-adoption and session-economics model

The home-adoption and session-economics model tracks, for 30 countries, the share of patients on home dialysis against policy targets, the equipment cost of a session by modality and setting, and the uptake of kidney-protecting drugs, so suppliers can see where home platforms will sell. Related markets are covered in the Wound Care Market, Continuous Glucose Monitoring Sensor Manufacturing Market and Hospital Sterile Processing Department Equipment Market reports.

Methodology and receipts

The dialysis equipment model is built bottom-up from treatments. The headline receipt is about 624 million treatments multiplied by USD 30.83 of equipment per treatment, giving USD 19.2 billion for 2025. Patient numbers come from national kidney registries in 30 countries, treatments from modality and frequency, and equipment content from product prices, dialyzer and fluid use, and machine replacement cycles, reconciled with the revenue of listed makers. Home and in-centre patients are modelled separately, with PD fluid use of four to five exchanges a day and haemodialysis at about three sessions a week, and the effect of kidney-protecting drugs is applied as a documented reduction in new patients from 2027. The forecast compounds 4.2% treatment growth and 1.2% revenue-per-treatment growth from the 2025 base to about 942 million treatments and USD 32.7 billion in 2035.

Sources

1. U.S. Securities and Exchange Commission (EDGAR) Baxter International Form 8-K/A Exhibit 99.1: completed sale of Kidney Care (Vantive) to Carlyle (2025)
2. World Health Organization WHO Global Health Observatory: noncommunicable disease indicators (2026)
3. United Nations Statistics Division UN Comtrade: trade flows in medical instruments and appliances (2026)